Sinovac Biotech PE Ratio 2006-2020 | SVA

Current and historical p/e ratio for Sinovac Biotech (SVA) from 2006 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sinovac Biotech PE ratio as of October 26, 2021 is 6.47.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Sinovac Biotech PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-02-22 6.47 inf
2018-12-31 6.94 0 0.00
2018-09-30 7.62 $0.08 95.25
2018-06-30 7.46 $0.14 53.29
2018-03-31 8.61 $-0.03 0.00
2016-12-31 5.90 $-0.01 0.00
2016-09-30 5.90 $-0.08 0.00
2016-06-30 5.93 $-0.17 0.00
2016-03-31 6.39 $0.04 159.75
2015-12-31 5.72 $-0.02 0.00
2015-09-30 5.08 $-0.01 0.00
2015-06-30 5.25 $0.02 262.50
2015-03-31 4.96 $-0.06 0.00
2014-12-31 5.23 $-0.02 0.00
2014-09-30 4.81 $0.06 80.17
2014-06-30 5.64 $0.10 56.40
2014-03-31 7.20 $0.16 45.00
2013-12-31 6.12 $0.12 51.00
2013-09-30 5.98 $-0.08 0.00
2013-06-30 3.93 $-0.18 0.00
2013-03-31 3.72 $-0.22 0.00
2012-12-31 3.14 $-0.28 0.00
2012-09-30 2.52 $-0.13 0.00
2012-06-30 2.11 $-0.11 0.00
2012-03-31 2.04 $-0.07 0.00
2011-12-31 2.20 $-0.02 0.00
2011-09-30 2.23 $-0.24 0.00
2011-06-30 3.20 $-0.21 0.00
2011-03-31 4.53 $-0.21 0.00
2010-12-31 4.52 $-0.17 0.00
2010-09-30 3.90 $0.21 18.57
2010-06-30 4.63 $0.34 13.62
2010-03-31 5.91 $0.46 12.85
2009-12-31 6.33 $0.47 13.47
2009-09-30 8.29 $0.32 25.91
2009-06-30 3.95 $0.22 17.95
2009-03-31 1.46 $0.16 9.13
2008-12-31 1.38 $0.20 6.90
2008-09-30 2.50 $0.19 13.16
2008-06-30 3.25 $0.22 14.77
2008-03-31 3.64 $0.14 26.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.642B $0.511B
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86